Arclight Capital Holdings LLC

Eaton Vance Management is a division of Eaton Vance who plays a role in the investment industry as a wealth manager. The company offers products that address all phases of an investor's lifetime, such as the creation and growth of wealth, the protection and preservation of its value and the distribution of wealth. It emphasizes tax efficiency. Eaton Vance and its affiliates have managed nearly $114 billion in assets as of Jan. 31, 2006, for more than 100 investment companies, as well as individual and institutional accounts that includes those of corporations, hospitals, retirement plans, universities, foundations and trusts. The 1979 merger of two Boston-based investment firms formed the company, Eaton & Howard, established in 1924, and Vance, Sanders & Company, established in 1934. Eaton Vance Management is headquartered in Boston.

CRE Asset Advisors, LLC is a trusted provider of dependable real estate intelligence and loan facilitation consulting services in Wellesley, MA. Their team of certified appraisers and analysts, with over 100 years of combined experience, offers comprehensive real estate valuation and consulting services for a wide range of commercial property types. They specialize in conducting in-depth analyses, market research, property site inspections, and environmental assessments to provide clients with accurate insights and informed investment decisions. With a focus on building long-lasting client relationships, CRE Asset Advisors leverages their expertise and professional relationships to facilitate real estate transactions. Their tailored consulting and evaluation services support both debt and equity investors, offering solutions to various valuation problems. Whether it's a full appraisal or a simple value estimate, their analysis enhances the underwriting process and helps clients make shrewd business decisions based on their specific criteria.Generated from the website

Inotek Pharmaceuticals is a privately held biotechnology company based in Lexington, MA, specializing in the discovery and development of innovative treatments for serious ocular diseases. With a robust pipeline focusing on conditions such as glaucoma and age-related macular degeneration, the company employs a scientifically rigorous approach to advance its lead drug candidate, trabodenoson INO-8875, which effectively addresses elevated intraocular pressure. The firm is supported by an experienced management team with a proven track record of successful New Drug Applications (NDAs), aiming to bring its clinical programs to commercialization. In addition to its advanced drug development platform, Inotek offers a range of effective, over-the-counter eye drops for glaucoma, ensuring high-quality products through collaboration with official suppliers and manufacturers. Generated from the website